Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Guru P. Sonpavde MD Advisory Board

See All Experts

story of the week

Published in Oncology and

Journal Scan / Research · January 25, 2023

Outcomes of Palbociclib Rechallenge in Patients With HR+/HER2− Advanced Breast Cancer

Clinical Cancer Research

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Sara Tolaney MD, MPH

Clinical Cancer Research

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Clin. Cancer Res 2023 Jan 04;29(1)67-80, J Albanell, JM Pérez-García, M Gil-Gil, G Curigliano, M Ruíz-Borrego, L Comerma, J Gibert, M Bellet, B Bermejo, L Calvo, J de la Haba, E Espinosa, AM Minisini, V Quiroga, A Santaballa Bertran, L Mina, B Bellosillo, F Rojo, S Menéndez, M Sampayo-Cordero, C Popa, A Malfettone, J Cortés, A Llombart-Cussac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Metastatic Breast Cancer

Outcomes of Palbociclib Rechallenge in Patients With HR+/HER2− Advanced Breast Cancer

Additional Info

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Further Reading

Radiotherapy With Cetuximab or Durvalumab for Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

Ramucirumab Plus Paclitaxel as Switch Maintenance vs Continuation of First-Line Oxaliplatin-Based Chemotherapy in Patients With Advanced HER2-Negative Gastric or Gastro-Oesophageal Junction Cancer

Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma

Neoadjuvant and Adjuvant Toripalimab for Locoregionally Advanced Nasopharyngeal Carcinoma

ASH 2024: Abstract Recommendations From Drs. Evani Patel and David Henry

ASH 2024: Abstract Recommendations From Dr. Rafael Fonseca

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Disease-Free Survival as a Surrogate for Overall Survival in Esophageal Cancer in Real-World Settings

Long-Term Outcomes After Adding a Contact X-Ray Brachytherapy Boost to Standard Neoadjuvant Chemoradiotherapy for Organ Preservation in Patients With Early Rectal Adenocarcinoma

Comparison of First-Line Chemotherapy Regimens in Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery in Patients With Stage III Soft Tissue Sarcoma of the Extremity

Recently Updated